Interactions between celexa(citalopram) and Azilect (rasagiline)
citalopram and rasagiline (Major Drug-Drug)
GENERALLY AVOID: Rasagiline, a monoamine oxidase (MAO)-B inhibitor, may potentiate the pharmacologic activity of selective serotonin reuptake inhibitors (SSRIs) and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors and characterized by symptoms such as CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia. The mechanism is an additive pharmacodynamic effect resulting from MAOI inhibition of serotonin metabolism.
MANAGEMENT: In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity. At least 14 days should elapse between discontinuation of rasagiline therapy and initiation of treatment with SSRIs, and vice versa.
